Platelet function in patients with depression

Southern Medical Journal

Volumn 101, Issue 6, 2008, Pages 612-617

  Parakh, Kapil ^a,b   Sakhuja, Ankit ^c   Bhat, Utsav ^c   Ziegelstein, Roy C ^c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BAYVIEW MEDICAL CENTER   (United States)

^c NONE

Author keywords

Cardiovascular diseases; Depression; Platelets; Selective serotonin reuptake inhibitor; Serotonin

Indexed keywords

ACETYLSALICYLIC ACID; ANTIDEPRESSANT AGENT; ANTITHROMBOCYTIC AGENT; BIOLOGICAL MARKER; CLOPIDOGREL; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; IMIPRAMINE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY GA6; NORADRENALIN; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; UNCLASSIFIED DRUG;

ACUTE CORONARY SYNDROME; ATHEROSCLEROSIS; BLEEDING; CARDIAC ENZYME BLOOD LEVEL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL INTERACTION; CENTRAL NERVOUS SYSTEM; CLINICAL ASSESSMENT; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DEPRESSION; DISEASE ASSOCIATION; DISEASE COURSE; DRUG BINDING; DRUG EFFICACY; HEART FAILURE; HEART MUSCLE ISCHEMIA; HUMAN; META ANALYSIS; REVIEW; SEROTONINERGIC SYSTEM; SIDE EFFECT; SYSTEMATIC REVIEW; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOSIS; BLOOD; DRUG EFFECT; PHYSIOLOGY; RISK FACTOR;

CARDIOVASCULAR DISEASES; DEPRESSIVE DISORDER; HUMANS; PLATELET ACTIVATION; RISK FACTORS; SEROTONIN UPTAKE INHIBITORS;

EID: 45149086033     PISSN: 00384348     EISSN: None     Source Type: Journal    
DOI: 10.1097/SMJ.0b013e318172f732     Document Type: Review

References (43)

1. Thombs BD, Bass EB, Ford DE, et al. Prevalence of depression in survivors of acute myocardial infarction: review of the evidence. J Gen Intern Med 2006;21:30-38.
2. Nicholson A, Kuper H, Hemingway H. Depression as an aetiologic and prognostic factor in coronary heart disease: a meta-analysis of 6362 events among 146,538 participants in 54 observational studies. Eur Heart J 2006;27:2763-2774.
3. Atkins D, Best D, Briss PA, et al. Grading quality of evidence and strength of recommendations. BMJ 2004;328:1490.
4. van Zwieten PA. Pathophysiological relevance of serotonin. J Cardiovasc Pharmacol 1987;10(suppl 3):S19-S25.
5. Skop BP, Brown TM. Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors. Psychosomatics 1996;37:12-16.
6. Massberg S, Brand K, Gruner S, et al. A critical role of platelet adhesion in the initiation of atherosclerotic lesion formation. J Exp Med 2002; 196:887-896.
7. Palmar M, Marcano A, Castejon O. Fine structural alterations of blood platelets in depression. Biol Psychiatry 1997;42:965-968.
8. Lesch KP, Wolozin BL, Murphy DL, et al. Primary structure of the human platelet serotonin uptake site: identity with the brain serotonin transporter. J Neurochem 1993;60:2319-2322.
9. Lechin F, van der Dijs B, Orozco B, et al. Elective stenting, platelet serotonin and thrombotic events. Platelets 2004;15:462.
10. Muck-Seler D, Pivac N, Mustapic M, et al. Platelet serotonin and plasma prolactin and cortisol in healthy, depressed and schizophrenic women. Psychiatry Res 2004;127:217-226.
11. Pivac N, Muck-Seler D, Sagud M, et al. Long-term sertraline treatment and peripheral biochemical markers in female depressed patients. Prog Neuropsychopharmacol Biol Psychiatry 2003;27:759-765.
12. Muck-Seler D, Jakovljevic M, Pivac N. Platelet 5-HT concentrations and suicidal behaviour in recurrent major depression. J Affect Disord 1996; 39:73-80.
13. Franke L, Schewe HJ, Muller B, et al. Serotonergic platelet variables in unmedicated patients suffering from major depression and healthy subjects: relationship between 5HT content and 5HT uptake. Life Sci 2000; 67:301-305.
14. Uebelhack R, Franke L, Herold N, et al. Brain and platelet serotonin transporter in humans-correlation between [123I]-ADAM SPECT and serotonergic measurements in platelets. Neurosci Lett 2006;406:153- 158.
15. Arora RC, Meltzer HY. Increased serotonin2 (5-HT2) receptor binding as measured by 3H-lysergic acid diethylamide (3H-LSD) in the blood platelets of depressed patients. Life Sci 1989;44:725-734.
16. Hrdina PD, Bakish D, Ravindran A, et al. Platelet serotonergic indices in major depression: up-regulation of 5-HT2A receptors unchanged by an-tidepressant treatment. Psychiatry Res 1997;66:73-85.
17. McBride PA, Brown RP, DeMeo M, et al. The relationship of platelet 5-HT2 receptor indices to major depressive disorder, personality traits, and suicidal behavior. Biol Psychiatry 1994;35:295-308.
18. Eckert A, Gann H, Riemann D, et al. Elevated intracellular calcium levels after 5-HT2 receptor stimulation in platelets of depressed patients. Biol Psychiatry 1993;34:565-568.
19. Kusumi I, Koyama T, Yamashita I. Serotonin-induced platelet intracellular calcium mobilization in depressed patients. Psychopharmacology (Berl) 1994;113:322-327.
20. Shimbo D, Child J, Davidson K, et al. Exaggerated serotonin-mediated platelet reactivity as a possible link in depression and acute coronary syndromes. Am J Cardiol 2002;89:331-333.
21. Gomez-Gil E, Gasto C, Carretero M, et al. Decrease of the platelet 5-HT2A receptor function by long-term imipramine treatment in endogenous depression. Hum Psychopharmacol 2004;19:251-258.
22. McAdams C, Leonard BE. Changes in platelet aggregatory responses to collagen and 5-hydroxytryptamine in depressed, schizophrenic and manic patients. Int Clin Psychopharmacol 1992;7:81-85.
23. Mendelson SD. The current status of the platelet 5-HT(2A) receptor in depression. J Affect Disord 2000;57:13-24.
24. Ellis PM, Salmond C. Is platelet imipramine binding reduced in depression? A meta-analysis. Biol Psychiatry 1994;36:292-299.
25. Lawrence KM, Falkowski J, Jacobson RR, et al. Platelet 5-HT uptake sites in depression: three concurrent measures using [3H] imipramine and [3H] paroxetine. Psychopharmacology (Berl) 1993;110:235-239.
26. D'haenen H, De Waele M, Leysen JE. Platelet 3H-paroxetine binding in depressed patients. Psychiatry Res 1988;26:11-17.
27. Walsh MT, Dinan TG, Condren RM, et al. Depression is associated with an increase in the expression of the platelet adhesion receptor glycoprotein Ib. Life Sci 2002;70:3155-3165.
28. Musselman DL, Tomer A, Manatunga AK, et al. Exaggerated platelet reactivity in major depression. Am J Psychiatry 1996;153:1313-1317.
29. Musselman DL, Marzec UM, Manatunga A, et al. Platelet reactivity in depressed patients treated with paroxetine: preliminary findings. Arch Gen Psychiatry 2000;57:875-882.
30. Piletz JE, Zhu H, Madakasira S, et al. Elevated P-selectin on platelets in depression: response to bupropion. J Psychiatr Res 2000;34:397-404.
31. Serebruany VL, Glassman AH, Malinin AI, et al. Enhanced platelet/ endothelial activation in depressed patients with acute coronary syndromes: evidence from recent clinical trials. Blood Coagul Fibrinolysis 2003;14:563-567.
32. Nair S, Kulkarni S, Camoens HM, et al. Changes in platelet glycoprotein receptors after smoking - a flow cytometric study. Platelets 2001;12: 20-26.
33. Quintana J. Platelet MAO deamination of serotonin in depressed patients. Changes after imipramine treatment and clinical correlations. Biol Psychiatry 1988;23:44-52.
34. Reveley MA, Glover V, Sandler M, et al. Increased platelet monoamine oxidase activity in affective disorders. Psychopharmacology (Berl) 1981; 73:257-260.
35. Wahlund B, Saaf J, Wetterberg L. Classification of patients with affective disorders using platelet monoamine oxidase activity, serum mela-tonin and post-dexamethasone cortisol. Acta Psychiatr Scand 1995;91: 313-321.
36. Garcia-Sevilla JA, Ventayol P, Perez V, et al. Regulation of platelet alpha 2A-adrenoceptors, Gi proteins and receptor kinases in major depression: effects of mirtazapine treatment. Neuropsychopharmacology 2004;29:580-588.
37. Werstiuk ES, Auffarth SE, Coote M, et al. Platelet alpha 2-adrenergic receptors in depressed patients and healthy volunteers: the effects of desipramine. Pharmacopsychiatry 1992;25:199-206.
38. Maurer-Spurej E, Pittendreigh C, Solomons K. The influence of selective serotonin reuptake inhibitors on human platelet serotonin. Thromb Haemost 2004;91:119-128.
39. Serebruany VL. Selective serotonin reuptake inhibitors and increased bleeding risk: are we missing something? Am J Med 2006;119:113-116.
40. Markovitz JH, Shuster JL, Chitwood WS, et al. Platelet activation in depression and effects of sertraline treatment: an open-label study. Am J Psychiatry 2000;157:1006-1008.
41. Glassman AH, O'Connor CM, Califf RM, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA 2002;288:701-709.
42. Sauer WH, Berlin JA, Kimmel SE. Selective serotonin reuptake inhibitors and myocardial infarction. Circulation 2001;104:1894-1898.
43. Ziegelstein RC, Meuchel J, Kim TJ, et al. Selective serotonin reuptake inhibitors in hospitalized acute coronary syndrome patients. Am J Med 2007;120:525-530.